Trump Administration Signals Deference To Congress On Drug Pricing Policy
Executive Summary
In a marked departure from previous years, budget proposal offers few specifics on cost reductions, but the $135bn savings estimate is a tacit endorsement of the Grassley-Wyden bill in the Senate.
You may also be interested in...
Trump Halt To US Funding For WHO: Making Global Health, Government Organization Potent Issues
Selling government efficiency as a campaign issue has not been an easy task for Democrats. COVID-19 – and especially support for international responses – may present a new opportunity.
Rx List Price Inflation Penalty Endorsed By US HHS Secretary
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
Drug Pricing Avoids The Limelight During State Of The Union Address
President Trump did not offer any new proposals on drug pricing during an evening featuring campaign theatrics on both sides.